Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma

Intrahepatic cholangiocarcinoma (iCCA) has emerged as a promising candidate for precision medicine, especially in the case of activating FGFR2 gene fusions. In addition to fusions, a considerable fraction of iCCA patients reveals FGFR2 mutations, which might lead to uncontrolled activation of the FG...

Descripción completa

Detalles Bibliográficos
Autores principales: Bitzer, Michael, Spahn, Stephan, Babaei, Sepideh, Horger, Marius, Singer, Stephan, Schulze-Osthoff, Klaus, Missios, Pavlos, Gatidis, Sergios, Nann, Dominik, Mattern, Sven, Scheble, Veit, Nikolaou, Konstantin, Armeanu-Ebinger, Sorin, Schulze, Martin, Schroeder, Christopher, Biskup, Saskia, Beha, Janina, Claassen, Manfred, Ruhm, Kristina, Poso, Antti, Malek, Nisar P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417271/
https://www.ncbi.nlm.nih.gov/pubmed/34480077
http://dx.doi.org/10.1038/s41698-021-00220-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417271/
https://www.ncbi.nlm.nih.gov/pubmed/34480077
http://dx.doi.org/10.1038/s41698-021-00220-0

Ejemplares similares